Denovo Biopharma

An Advisor Team Consists of Industry Veterans and Academic Leaders

K. Peter Hirth, Ph.D.

Dr. Hirth has over 30 years of biotechnology and pharmaceutical discovery and development experience, and is a pioneer in advancing personalized medicine. He was a co-founder and CEO of Plexxikon where he built a novel, structure-guided drug discovery platform, which over the last ten years, has brought several NCEs into the clinic in a variety of indications. From this portfolio, a V600E B-raf selective inhibitor that was FDA approved for metastatic melanoma together with a companion diagnostic and is sold under the brand name Zelboraf™, one of the most recent success in biomarker guided drug development frequently cited as prime example of personalized medicine. Previously worked in Boehringer Mannheim, Sugen, and Plexxikon.

Steven Leventer , Ph.D.

28 years of experience in all phases of drug development. Skill set derived from large Pharma, startup, and CRO seasoning. Overall experience includes direction of well over 100 clinical trials, from single studies to entire development programs across multiple indications and all phases of drug development. Extensive interactive experience with national regulatory agencies, has led multiple regulatory meetings with FDA and EU Boards of Health. Highly entrepreneurial drug developer with excellent financial and strong management skills. Previously worked in Quintiles, Vela Pharmaceuticals, Wyeth, and Astra Zeneca.

Daniel Pertschuk, M.D.

Board certified internist with over twenty years of experience in drug development especially in oncology, and has worked on small molecules, biologics, vaccines and gene therapies. Previously worked in Tacogen, Spectrum Pharmaceutical, CancerVax, Chugai Biopharmaceuticals, and Isis Pharmaceuticals .

John M. Davis, M.D.

Dr. Davis is world renowed phyisian sicentist in psychiatry clinical research. Dr. Davis is interested in the biologic basis of major mental illness and its treatment with medication. He and his colleagues introduced the paradigm to psychiatry that major mental illness may be caused by biochemical abnormalities. His group was among the first to do studies on the pharmacodynamics and pharmacokinetics of psychotropic drugs. His educational film to teach the recognition of certain side effects to physicians won a Telly award, the equivalent of an Academy Award for education industry films. He was among the first several physicians to introduce meta-analysis as a tool to pool scientific data.